Teva Pharmaceutical Industries stock faces R&D leadership change
Published on 11/20/2026 at 10:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTeva leadership transition
- David Gardiner will lead research and development during the transition and report to CEO Richard Francis.
- Eric Hughes will remain with Teva for several months while the company searches for a permanent successor.
- Teva reiterated its ambition to generate 6-7 billion US dollars in innovative medicines revenue by 2030.
Teva Pharmaceutical Industries Ltd. announced on November 18, 2026, that Eric Hughes, its executive vice president for global research and development and chief medical officer, will leave the company after accepting an external offer. The announcement was published by GlobeNewswire on behalf of Teva.
Leadership transition begins
David Gardiner, head of innovative medicines and clinical development, will serve as the transition lead for R&D with immediate effect. He will report directly to President and CEO Richard Francis while Teva conducts a comprehensive search for a permanent successor.
Hughes is expected to remain with Teva for the coming months to support the handover. The leadership change affects the management of the R&D organization, while the company said its strategy, priorities and expectations remain unchanged.
Pipeline plan remains intact
Teva said it remains focused on the commitments presented at its November 11 R&D Day. The company reiterated its ambition to generate 6-7 billion US dollars in innovative medicines revenue by 2030 as it advances its pipeline in neuroscience, immunology and other areas alongside its generics and biosimilars businesses.
Teva Pharmaceutical Industries profile
- Company: Teva Pharmaceutical Industries Ltd.
- ISIN: US8816242098
- Ticker: TEVA
- Listings: New York Stock Exchange and Tel Aviv Stock Exchange
Teva is listed on the S&P 500 market, where large US-listed companies are tracked.
More news and analyses on Teva Pharmaceutical Industries stock
